Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CanSino BiologicsCASBF 69 Market Cap is $1,246.37 Mil as of Jul. 14, 2026. GuruFocus rates CASBF with a GF Score™ of 69/100 and a GF Value™ of $8.72 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,024 Drug Manufacturers companies, CanSino Biologics ranks better than 78.12% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). CanSino Biologics's share price for the quarter that ended in Dec. 2025 was $4.745. CanSino Biologics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 247.04 Mil. Therefore, CanSino Biologics's market cap for the quarter that ended in Dec. 2025 was $1,172.22 Mil.
CanSino Biologics's quarterly market cap
increased
from Jun. 2025 ($791.84 Mil) to Sep. 2025 ($1,630.49 Mil) but then
declined
from Sep. 2025 ($1,630.49 Mil) to Dec. 2025 ($1,172.22 Mil).
CanSino Biologics's annual market cap
increased
from Dec. 2023 ($730.47 Mil) to Dec. 2024 ($990.05 Mil) and
increased
from Dec. 2024 ($990.05 Mil) to Dec. 2025 ($1,172.22 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. CanSino Biologics's Enterprise Value for Today is $1,033.33 Mil.
CanSino Biologics (OTCPK:CASBF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
CanSino Biologics Market Cap Related Terms
CanSino Biologics Market Cap Historical Data
* Premium members only.
The historical data trend for CanSino Biologics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanSino Biologics Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's Market Cap distribution charts can be found below:
* The bar in red indicates where CanSino Biologics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
CanSino Biologics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanSino Biologics (CASBF) has a Market Cap of $1,246.37 Mil as of Jul. 14, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on CanSino Biologics and its competitors. According to the industry distribution chart, CanSino Biologics ranks #224 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 21.9%.
Is CanSino Biologics' Market Cap too high?
CanSino Biologics' current Market Cap is $1,246.37 Mil. The Drug Manufacturers industry median Market Cap is 211.96. CanSino Biologics' value of $1,246.37 Mil is 488% above this industry median. Based on the distribution chart, CanSino Biologics ranks #224 out of 1024 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, CanSino Biologics has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CanSino Biologics' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, CanSino Biologics ranks #224 out of 1024 companies for Market Cap. This places CanSino Biologics in the top 22% of its industry — outperforming the majority of peers. The industry median Market Cap is 211.96. CanSino Biologics' value of $1,246.37 Mil is 488% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 211.96, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CanSino Biologics's current Market Cap of $1,246.37 Mil is 488% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on CanSino Biologics and its competitors. For the Drug Manufacturers industry, the median Market Cap is 211.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanSino Biologics's current Market Cap is $1,246.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanSino Biologics stock overvalued right now?
Based on GuruFocus' analysis, CanSino Biologics (CASBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $8.72, compared to a current price of $2.60 — trading 70.2% below its estimated fair value. The current Market Cap is $1,246.37 Mil and 488% above the Drug Manufacturers industry median of 211.96. CanSino Biologics' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For CanSino Biologics (CASBF), the current Market Cap is $1,246.37 Mil as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CanSino Biologics (CASBF) Overvalued in 2026?
Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued.
The current stock price of $2.60 is trading 70.2% below its estimated GF Value™ of $8.72.
GuruFocus considers CanSino Biologics to be Significantly Undervalued.
Key valuation signals for CASBF:
Market Cap: $1,246.37 Mil
GF Value™: $8.72 vs. price of $2.60 (70.2% below fair value)
Industry Position: 488% above the Drug Manufacturers median (#224 of 1024)
No single metric tells the full story. See the CASBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
69GF Score
Get the complete analysis for CASBF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CASBF has been successfully added to your 
